Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NVA237 100 µg · 1 trial · 1 indication
The assessment of safety was based on adverse events, particularly those adverse events known to be associated to treatment with muscarinic antagonists. A summary of adverse events is presented with this outcome, additional details are provided in Adverse Events Sections.
| Arm | Type | Description |
|---|---|---|
| NVA237 100 µg | EXPERIMENTAL | - |
| NVA237 200 µg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NVA237 100 µg | DRUG | Dry powder inhalation once a day for up to 28 days |
| Placebo | DRUG | Placebo to NVA237 dry powder inhalation once a day for up to 28 days |
| NVA237 200 µg | DRUG | Dry powder inhalation once a day for up to 28 days |
Inclusion Criteria: * Male or female adults aged 40 years or older * Patients with moderate to severe COPD according to the GOLD Guidelines (2006) * Patients who have smoking history of at least 10 pack years * Patients with a post-bronchodilator Forced Expiratory Volume in One Second (FEV1) equal ...
NVA237 100 µg is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is a glycopyrronium bromide formulation studied in patients with moderate to severe COPD. The drug is not approved and remains in clinical development.
NVA237 100 µg is a small molecule containing glycopyrronium bromide, an anticholinergic agent. It is being studied for its safety and tolerability in patients with moderate to severe COPD. The specific molecular target is not disclosed in the available information.
NVA237 100 µg is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The drug is currently in Phase 2 clinical development for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
NVA237 100 µg is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD) in patients with moderate to severe disease.
NVA237 100 µg has one completed clinical trial, registered as NCT00510510. This Phase 2 study evaluated the safety and tolerability of 28 days of treatment with glycopyrronium bromide (NVA237) at 100 or 200 µg once daily in 281 patients with moderate to severe COPD. The trial was randomized, double-blind, and placebo-controlled.
NVA237 100 µg is a formulation of glycopyrronium bromide, an anticholinergic bronchodilator. The drug is being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The 100 µg dose refers to the amount of glycopyrronium bromide administered once daily in the clinical trial.